For the fourth consecutive year, physicians ranked Pfizer reps as the pharmaceutical sales division that provides the most value to their practices.
According to Scott-Levin's annual survey, "Sales Force Structures & Strategies, 1998-1999," general and family practitioners, cardiologists, general surgeons and psychiatrists rated Pfizer above competitors. And, among the nine core specialty groups included in the survey, Pfizer came out on top.
Several factors helped tip the scales in Pfizer's favor in 1998, according the Newtown, PA-based consulting firm.
For one, the company launched Viagra for erectile dysfunction, a product that garnered widespread media and consumer interest. Physicians' need for information about the heavily requested drug effectively opened the door to sales reps with answers to their questions. Second, the company added Alta, its fifth sales force, for an additional 650 bodies in the field. The Alta force targeted primary care physicians.
Pfizer also launched Lipitor, a cholesterol reducer that the company copromotes with Parke-Davis, and developed a direct-to-consumer advertising campaign for Aricept, a product indicated for the treatment of Alzheimer's disease.
However, other sales forces earned the respect of certain customers, too.
Merck, for example, was rated number one by internal medicine specialists, nephrologists and endocrinologists. Glaxo Wellcome was rated best by pulmonologists and neurologists.
Wyeth-Ayerst, meanwhile, scored well with OB/GYNs and orthopedic surgeons, and Schering-Plough earned the nod from allergists and otorhinolaryngologists.
Gastroenterologists cited Astra Merck as their favorite, and pediatricians named Ross as their top pick in terms of salespeople. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.